Developer docs
API playgroundTry for free, no card

Search company profiles

Ceban Pharmaceuticals

Full company profile

uuid000k7av

Namestring
Ceban Pharmaceuticals
Legal namestring
Ceban Pharmaceuticals B.V.
Websiteurl
cebanpharma.com
Company typeenum
Private
Founded yearint
1980
Descriptiontext

Ceban Pharmaceuticals is a Dutch-headquartered international specialty pharma platform serving local healthcare providers in the Netherlands, Belgium, and Spain. The group operates eight subsidiaries spanning the pharmaceutical value chain: API/raw materials distribution (Magis Pharma in Belgium, Metapharmaceutical in Spain), central GMP compounding pharmacy services (Ceban Compounding, Meppel), pharmacy retail through the owned Medsen Apotheek collective (~50 pharmacies), hospital and clinic supply (Ceban Clinic Services, 200+ hospitals), medicine and diagnostics distribution (Bipharma), home administration of specialist medicines and patient coaching (Ceban HomeCare, 55+ BIG-registered nurses), and pharmacy automation hardware (Pharmaself24 vending machines, Q-Manager queue systems, narrowcasting — Ceban Automation). Ceban's core proposition is personalised medication preparation for vulnerable patients (e.g. children) whose needs are not commercially served by large pharma manufacturers, combined with integrated back-office and automation services for independent pharmacies.

The company runs a B2B, sales-led go-to-market targeting pharmacies, hospital pharmacies, clinics, and laboratories via direct field sales, supported by an inbound website and newsletter funnel. Revenue is generated through transaction-fee streams (compounding supply, raw materials distribution, medicine/diagnostics distribution, hospital supply), hardware sales plus service for pharmacy automation, and professional services for home care. Pricing is not publicly disclosed and is quote-based across most lines. Operationally, the platform handles 500+ pharmaceutical raw materials, produces 15,000 personalised medication preparations per year, performs 20,000 specialist home procedures annually, and reaches 4 million patients through installed vending machines.

In June 2024, Ceban Pharmaceuticals B.V. was acquired by Medios AG, a publicly-listed German Specialty Pharma solutions provider, following NZa regulatory approval and Works Council advice; prior to that, Bencis Capital Partners had been the financial investor since 2019, having backed a multi-year buy-and-build strategy that built the eight-company group from a domestic wholesale/pharmacy heritage dating back to 1980 (as Regifarm).

Short descriptiontext

Ceban Pharmaceuticals is a Dutch-based specialty pharma platform operating eight subsidiaries across the Netherlands, Belgium, and Spain, delivering compounded medicines, APIs, pharmacy automation, hospital supply, and home care to 200+ hospitals and 3,300+ pharmacies.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBreda, Netherlands
HQ citystring
Breda
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical compounding, specialty pharmaceuticals, pharmacy automation, pharmaceutical distribution, home healthcare services
Industry4 codes
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAFALAC
Specialty Pharmacies (Complex/High-Cost Therapies)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAFALAB
Hospital & Health-System Pharmacies (Inpatient/Outpatient)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Pharmacies and Drug Retailers456110
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Retail-Drug Stores And Proprietary Stores5912
Product category
Specialty Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model6 records
1Compounding pharmacy services
TypeTransaction Fee
Description

Supply of customised medicines to dispensing pharmacies in Netherlands and Belgium. Central compounding pharmacy preparing medicines the pharmaceutical industry does not produce commercially.

cebanpharma.com
2Pharmaceutical raw materials distribution
TypeTransaction Fee
Description

Distribution of APIs (active pharmaceutical ingredients) to support pharmacies in magistral preparation of custom-made medicines

cebanpharma.com
3Specialized medicines distribution
TypeTransaction Fee
Description

Distribution of limited-access medicines and medical diagnostics through Bipharma subsidiary

cebanpharma.com
4Home healthcare services
TypeProfessional Services
Description

Home administration of specialist medicines, patient coaching, vaccination programmes and prick accident handling through Ceban HomeCare

cebanpharma.com
5Pharmacy automation solutions
TypeHardware Sales
Description

Sale and service of Pharmaself24 vending machines, Q-Manager queue systems and narrowcasting solutions to pharmacies

cebanpharma.com
6Hospital pharmacy services
TypeTransaction Fee
Description

Supply of medicines and medical supplies to clinics and independent treatment centers through Ceban Clinic Services

cebanpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ceban Pharmaceuticals operates an international pharmaceutical platform providing compounding of customised medicines, distribution of pharmaceutical raw materials (APIs), pharmacy automation solutions, hospital pharmacy services, and home-based specialist medication administration. The group serves 200+ hospitals and 3,300+ pharmacies across the Netherlands, Belgium and Spain through eight operating companies, including GMP-certified production facilities, an owned pharmacy chain of ~50 outlets, and a nurse network performing 20,000+ home procedures annually.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 15,000 personalised medication preparations per year
+3 more records
Product overview1 text field

Ceban Pharmaceuticals is a growing international healthcare platform offering pharmaceutical solutions for local healthcare providers across the Netherlands, Belgium, and Spain. The company operates a platform-plus-subsidiaries architecture consisting of 8 companies. The core offerings include Ceban Compounding (central GMP compounding pharmacy preparing customized medicines), Ceban Automation (Pharmaself24, Q-Manager, Pharma Channel for pharmacy automation), and Ceban Clinic Services (national hospital pharmacy). Subsidiary brands include Medsen Apotheek (chain of ~50 pharmacies), Magis Pharma (Belgian API distributor), Metapharmaceutical (Spanish pharmaceutical raw materials producer), Bipharma (medicine and diagnostic distributor), and Ceban HomeCare (home medication administration services). The platform serves over 200 hospitals and 3,300 pharmacies, delivering 15,000 personalized medication preparations annually, with 600 employees across 8 companies.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German listed Specialty Pharma platform and Ceban's acquirer (June 2024). Directly comparable on compounding, patient-individual therapies, and specialty distribution across Germany, Netherlands, Belgium, and Spain.

TypeBroad incumbent
Description

One of Europe's largest pharmaceutical wholesale and retail pharmacy groups (owns BENU Apotheek, Brocacef). Overlaps with Ceban's pharmacy wholesale, retail pharmacy (Medsen), and compounding distribution.

3McKesson Europe (formerly Celesio)
TypeBroad incumbent
Description

European pharmaceutical distribution and pharmacy retail (Lloyds Apotheek) across multiple EU markets; a broad incumbent in the same distribution-and-pharmacy space Ceban plays in.

TypeDirect peer
Description

Dutch pharmaceutical distribution, compounding, and pharmacy services company owned by PHOENIX Group; directly comparable to Ceban's Ceban Compounding, Bipharma, and Medsen Apotheek operations in the Netherlands.

5Mosadex Groep
TypeDirect peer
Description

Dutch pharmacy cooperative and pharmaceutical wholesaler with compounding and home-care services; competes head-to-head with Ceban Compounding and Ceban HomeCare in the Netherlands.

TypeDirect peer
Description

Dutch pharmaceutical full-line wholesaler serving independent pharmacies; comparable to Ceban's distribution and pharmacy-supply activities in the Netherlands.

TypeDirect peer
Description

Specialty pharma company focused on compounding, hospital pharmacy, and home-care in the Netherlands; closely mirrors Ceban's compounding, clinic services, and HomeCare model.

TypeEmerging player
Description

European online pharmacy with mail-order dispensing; an emerging channel competitor to Ceban's Medsen Apotheek retail and home-delivery services, especially for repeat prescriptions.

TypeEmerging player
Description

Online pharmacy and prescription mail-order platform in Netherlands/Germany/Spain; competes with Medsen Apotheek's online ordering and 24/7 automated dispensing channel.

TypeRegional player
Description

European specialty ingredients and pharma raw materials distributor; comparable to Magis Pharma and Metapharmaceutical in API/excipient distribution to compounding pharmacies and hospitals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ceban Pharmaceuticals

Specialty Pharmaceuticalscebanpharma.com

Ceban Pharmaceuticals is a Dutch-based specialty pharma platform operating eight subsidiaries across the Netherlands, Belgium, and Spain, delivering compounded medicines, APIs, pharmacy automation, hospital supply, and home care to 200+ hospitals and 3,300+ pharmacies.

What Ceban Pharmaceuticals does

Ceban Pharmaceuticals is a Dutch-headquartered international specialty pharma platform serving local healthcare providers in the Netherlands, Belgium, and Spain. The group operates eight subsidiaries spanning the pharmaceutical value chain: API/raw materials distribution (Magis Pharma in Belgium, Metapharmaceutical in Spain), central GMP compounding pharmacy services (Ceban Compounding, Meppel), pharmacy retail through the owned Medsen Apotheek collective (~50 pharmacies), hospital and clinic supply (Ceban Clinic Services, 200+ hospitals), medicine and diagnostics distribution (Bipharma), home administration of specialist medicines and patient coaching (Ceban HomeCare, 55+ BIG-registered nurses), and pharmacy automation hardware (Pharmaself24 vending machines, Q-Manager queue systems, narrowcasting — Ceban Automation). Ceban's core proposition is personalised medication preparation for vulnerable patients (e.g. children) whose needs are not commercially served by large pharma manufacturers, combined with integrated back-office and automation services for independent pharmacies.

The company runs a B2B, sales-led go-to-market targeting pharmacies, hospital pharmacies, clinics, and laboratories via direct field sales, supported by an inbound website and newsletter funnel. Revenue is generated through transaction-fee streams (compounding supply, raw materials distribution, medicine/diagnostics distribution, hospital supply), hardware sales plus service for pharmacy automation, and professional services for home care. Pricing is not publicly disclosed and is quote-based across most lines. Operationally, the platform handles 500+ pharmaceutical raw materials, produces 15,000 personalised medication preparations per year, performs 20,000 specialist home procedures annually, and reaches 4 million patients through installed vending machines.

In June 2024, Ceban Pharmaceuticals B.V. was acquired by Medios AG, a publicly-listed German Specialty Pharma solutions provider, following NZa regulatory approval and Works Council advice; prior to that, Bencis Capital Partners had been the financial investor since 2019, having backed a multi-year buy-and-build strategy that built the eight-company group from a domestic wholesale/pharmacy heritage dating back to 1980 (as Regifarm).

Ceban Pharmaceuticals firmographics

Firmographics
Name
Ceban Pharmaceuticals
Legal name
Ceban Pharmaceuticals B.V.
Website
https://cebanpharma.com
Company type
Private
Founded year
1980
Operating status
Acquired
Headcount range
51–100 employees
Short description
Ceban Pharmaceuticals is a Dutch-based specialty pharma platform operating eight subsidiaries across the Netherlands, Belgium, and Spain, delivering compounded medicines, APIs, pharmacy automation, hospital supply, and home care to 200+ hospitals and 3,300+ pharmacies.
Ownership category
akta.pro rank

Ceban Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmacies and Drug Retailers (456110)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)
akta.pro industry
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAFALAC
Specialty Pharmacies (Complex/High-Cost Therapies)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAFALAB
Hospital & Health-System Pharmacies (Inpatient/Outpatient)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Pharmaceutical compounding
  • Specialty pharmaceuticals
  • Pharmacy automation
  • Pharmaceutical distribution
  • Home healthcare services

Where Ceban Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Breda
HQ country
Netherlands
HQ region
Europe

Offices7 records

Markets served

Ceban Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Compounding pharmacy services: Supply of customised medicines to dispensing pharmacies in Netherlands and Belgium. Central compounding pharmacy preparing medicines the pharmaceutical industry does not produce commercially.
  2. Pharmaceutical raw materials distribution: Distribution of APIs (active pharmaceutical ingredients) to support pharmacies in magistral preparation of custom-made medicines
  3. Specialized medicines distribution: Distribution of limited-access medicines and medical diagnostics through Bipharma subsidiary
  4. Home healthcare services: Home administration of specialist medicines, patient coaching, vaccination programmes and prick accident handling through Ceban HomeCare
  5. Pharmacy automation solutions: Sale and service of Pharmaself24 vending machines, Q-Manager queue systems and narrowcasting solutions to pharmacies
  6. Hospital pharmacy services: Supply of medicines and medical supplies to clinics and independent treatment centers through Ceban Clinic Services

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Ceban Pharmaceuticals product offering

Product offering

Core offering

Ceban Pharmaceuticals operates an international pharmaceutical platform providing compounding of customised medicines, distribution of pharmaceutical raw materials (APIs), pharmacy automation solutions, hospital pharmacy services, and home-based specialist medication administration. The group serves 200+ hospitals and 3,300+ pharmacies across the Netherlands, Belgium and Spain through eight operating companies, including GMP-certified production facilities, an owned pharmacy chain of ~50 outlets, and a nurse network performing 20,000+ home procedures annually.

Product overview

Ceban Pharmaceuticals is a growing international healthcare platform offering pharmaceutical solutions for local healthcare providers across the Netherlands, Belgium, and Spain. The company operates a platform-plus-subsidiaries architecture consisting of 8 companies. The core offerings include Ceban Compounding (central GMP compounding pharmacy preparing customized medicines), Ceban Automation (Pharmaself24, Q-Manager, Pharma Channel for pharmacy automation), and Ceban Clinic Services (national hospital pharmacy). Subsidiary brands include Medsen Apotheek (chain of ~50 pharmacies), Magis Pharma (Belgian API distributor), Metapharmaceutical (Spanish pharmaceutical raw materials producer), Bipharma (medicine and diagnostic distributor), and Ceban HomeCare (home medication administration services). The platform serves over 200 hospitals and 3,300 pharmacies, delivering 15,000 personalized medication preparations annually, with 600 employees across 8 companies.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • 15,000 personalised medication preparations per year
  • +3 more outcomes

Companies that use Ceban Pharmaceuticals

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles5 records

Ceban Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Ceban Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators13 records

Recent moves8 records

Expansion highlights5 records

Ceban Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Medios AG: German listed Specialty Pharma platform and Ceban's acquirer (June 2024). Directly comparable on compounding, patient-individual therapies, and specialty distribution across Germany, Netherlands, Belgium, and Spain.
  • Brocacef Groep: Dutch pharmaceutical distribution, compounding, and pharmacy services company owned by PHOENIX Group; directly comparable to Ceban's Ceban Compounding, Bipharma, and Medsen Apotheek operations in the Netherlands.
  • Mosadex Groep: Dutch pharmacy cooperative and pharmaceutical wholesaler with compounding and home-care services; competes head-to-head with Ceban Compounding and Ceban HomeCare in the Netherlands.
  • Pluripharm: Dutch pharmaceutical full-line wholesaler serving independent pharmacies; comparable to Ceban's distribution and pharmacy-supply activities in the Netherlands.
  • Eurocept Pharmaceuticals: Specialty pharma company focused on compounding, hospital pharmacy, and home-care in the Netherlands; closely mirrors Ceban's compounding, clinic services, and HomeCare model.

Broad incumbents

  • PHOENIX Group: One of Europe's largest pharmaceutical wholesale and retail pharmacy groups (owns BENU Apotheek, Brocacef). Overlaps with Ceban's pharmacy wholesale, retail pharmacy (Medsen), and compounding distribution.
  • McKesson Europe (formerly Celesio): European pharmaceutical distribution and pharmacy retail (Lloyds Apotheek) across multiple EU markets; a broad incumbent in the same distribution-and-pharmacy space Ceban plays in.

Emerging players

  • SHOP APOTHEKE EUROPE: European online pharmacy with mail-order dispensing; an emerging channel competitor to Ceban's Medsen Apotheek retail and home-delivery services, especially for repeat prescriptions.
  • DocMorris (Zur Rose Group): Online pharmacy and prescription mail-order platform in Netherlands/Germany/Spain; competes with Medsen Apotheek's online ordering and 24/7 automated dispensing channel.

Regional players

  • Caldic (Advent International): European specialty ingredients and pharma raw materials distributor; comparable to Magis Pharma and Metapharmaceutical in API/excipient distribution to compounding pharmacies and hospitals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Ceban Pharmaceuticals social profiles

Digital presence

Ceban Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ceban Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles9 records

Ceban Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Ceban Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ceban Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ceban Pharmaceuticals

What does Ceban Pharmaceuticals do?

Ceban Pharmaceuticals operates an international pharmaceutical platform providing compounding of customised medicines, distribution of pharmaceutical raw materials (APIs), pharmacy automation solutions, hospital pharmacy services, and home-based specialist medication administration. The group serves 200+ hospitals and 3,300+ pharmacies across the Netherlands, Belgium and Spain through eight operating companies, including GMP-certified production facilities, an owned pharmacy chain of ~50 outlets, and a nurse network performing 20,000+ home procedures annually.

Is Ceban Pharmaceuticals a public or private company?

Ceban Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.

When was Ceban Pharmaceuticals founded?

Ceban Pharmaceuticals was founded in 1980. It employs 51 to 100 people.

Where is Ceban Pharmaceuticals based?

Ceban Pharmaceuticals is headquartered in Breda, Netherlands, in the Europe region.

How does Ceban Pharmaceuticals make money?

Six revenue lines are on record. Compounding pharmacy services are the primary driver. The others are pharmaceutical raw materials distribution, specialized medicines distribution, home healthcare services, pharmacy automation solutions and hospital pharmacy services.

Who are Ceban Pharmaceuticals's main competitors?

Direct peers on record are Medios AG, Brocacef Groep, Mosadex Groep, Pluripharm and Eurocept Pharmaceuticals. Broad incumbents are PHOENIX Group and McKesson Europe (formerly Celesio). Emerging players are SHOP APOTHEKE EUROPE and DocMorris (Zur Rose Group). Caldic (Advent International) is listed as a regional player.

Does Ceban Pharmaceuticals have an API?

No public API is recorded for Ceban Pharmaceuticals.

What industry is Ceban Pharmaceuticals in?

Ceban Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of HLAFALAC, Specialty Pharmacies (Complex/High-Cost Therapies). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AD HOC NEWSGLP-1-Agonisten: Semaglutid zeigt gutes Sicherheitsprofil bei AugenNovo Nordisk secured an injunction in the Netherlands against Ceban Ziekenhuisfarmacie for manufacturing and selling an unapproved Semaglutid nasal spray, citing patent infringement. Concurrently, retrospective US data published in Ophthalmology indicated that Semaglutid does not increase the risk of neovascular age-related macular degeneration compared to other GLP-1 agonists or no medication.BenzingaNovo Nordisk Stock Is Gaining Thursday: What's Going On? - Novo Nordisk (NYSE:NVO)The District Court of The Hague ruled in favor of Novo Nordisk AG, issuing a preliminary injunction that forces Ceban Ziekenhuisfarmacie B.V. to immediately halt sales of an unauthorized semaglutide nasal spray and disclose its commercial supply chain. The court also ordered the compounding firm to remove product references and reimburse Novo Nordisk's legal expenses, reinforcing European safety regulations around unapproved drug formulations. The ruling comes as Novo Nordisk actively defends its GLP-1 franchise, which includes Wegovy, Ozempic, and Rybelsus, amid broader litigation with Eli Lilly over marketing practices.MarketScreenerDutch Court Grants Novo Nordisk Preliminary Injunction Against Ceban in Patent Dispute Over Semaglutide Nasal SprayA Dutch court has granted Novo Nordisk a preliminary injunction against Ceban in an ongoing patent dispute regarding a nasal spray formulation of semaglutide. This legal ruling prevents Ceban from marketing the competing product, thereby protecting Novo Nordisk's intellectual property rights in the European market. The decision represents a significant legal victory for Novo Nordisk in its efforts to maintain exclusivity over its obesity and diabetes treatments.Business InsiderEQS-News: Medios acquires Dutch market leader in pharmaceutical compounding servicesMedios AG acquired Dutch compounding leader Ceban Pharmaceuticals for €235.3 million cash plus 1.7 million shares, expected to close in Q2 2024. Ceban's 2023 revenue is expected at €160 million with an 18% margin. Medios projects FY2024 revenue of €1.9-2.1 billion and FY2025 revenue of €2.15 billion.Business InsiderEQS-Adhoc: Medios acquires Dutch market leader in pharmaceutical compounding servicesMedios AG acquired Dutch compounding services firm Ceban Pharmaceuticals for €235.3 million cash plus 1.7 million new shares. The deal, financed by existing cash and a €200 million credit facility, is expected to close in Q2 2024. Medios expects FY2024 revenue of €1.9–2.1 billion and EBITDA of €82–91 million.MediosNews detail view – MediosMedios AG announced the acquisition of Ceban Pharmaceuticals B.V., the Dutch market leader in pharmaceutical compounding, for a total value of approximately €259.2 million comprising cash and shares. This transaction is a strategic step in Medios' plan to build a leading European Specialty Pharma platform, with closing expected in the second quarter of 2024. The combined entity aims to leverage synergies and cross-selling opportunities across Germany, the Netherlands, Belgium, and Spain.PharmiWeb.comMedios acquires Dutch market leader in pharmaceutical compounding servicesMedios AG announced the acquisition of Ceban Pharmaceuticals B.V., a leading pharmaceutical compounding provider in the Netherlands, on March 18, 2024. The acquisition, valued at approximately €235.3 million in cash and shares, is part of Medios' strategy to build a leading European Specialty Pharma platform with expected significant growth in revenue and margins post-acquisition. This move positions Medios to benefit from expanding market opportunities in homecare and clinics across the Netherlands, Belgium, and Spain.